Featured Research

from universities, journals, and other organizations

Osteopontin contributes to allergic contact dermatitis

Date:
January 4, 2010
Source:
American Journal of Pathology
Summary:
Researchers in Germany have discovered that osteopontin (OPN) contributes to allergic contact dermatitis.

Dr. Johannes M. Weiss and colleagues at the University of Ulm, Ulm, Germany have discovered that osteopontin (OPN) contributes to allergic contact dermatitis.

They present these findings in the January 2010 issue of the American Journal of Pathology.

Allergic contact dermatitis is a hyperreaction of the immune system to either allergens or irritants on the skin, such as poison ivy, nickel, or latex. Contact dermatitis results in large, burning, and itchy rashes, which can take anywhere from several days to weeks to heal. Once allergic contact dermatitis occurs, only strict avoidance can prevent a recurrence, and there is no method to resist persistent sensitization.

Seier et al hypothesized that OPN, an immune mediator that has been shown to worsen the effects of autoimmune disease, played a role in eliciting and facilitating chronic allergic contact dermatitis. They found that both skin cells and immune cells secreted OPN in allergic contact dermatitis lesions. OPN was strongly induced in antigen-specific immune cells in a murine model of chronic contact hypersensitivity, and OPN-deficient mice had a less severe chronic contact hypersensitivity response. As anti-OPN antibody treatment partially suppressed the symptoms of chronic contact hypersensitivity, OPN may serve as a new therapeutic target for allergic contact dermatitis.

Dr. Weiss's group suggests that "[their] data support a model in which OPN has an important function for [immune]-mediated skin inflammation, which may open the perspective to use anti-OPN antibody preparations for the treatment of therapy refractory [immune] cell-mediated skin disease."


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Seier AM, Renkl AC, Schulz G, Uebele T, Sindrilaru A, Iben S, Liaw L, Kon S, Uede T Weiss JM. Antigen-Specific Induction of Osteopontin Contributes to the Chronification of Allergic Contact Dermatitis. American Journal Of Pathology, 2010; 176 (1): 246 DOI: 10.2353/ajpath.2010.090488

Cite This Page:

American Journal of Pathology. "Osteopontin contributes to allergic contact dermatitis." ScienceDaily. ScienceDaily, 4 January 2010. <www.sciencedaily.com/releases/2009/12/091230193136.htm>.
American Journal of Pathology. (2010, January 4). Osteopontin contributes to allergic contact dermatitis. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/12/091230193136.htm
American Journal of Pathology. "Osteopontin contributes to allergic contact dermatitis." ScienceDaily. www.sciencedaily.com/releases/2009/12/091230193136.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins